Denali Therapeutics (NASDAQ:DNLI) Posts Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Denali Therapeutics (NASDAQ:DNLI) posted its quarterly earnings data on Thursday. The company reported ($0.67) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.08, Zacks reports.

Denali Therapeutics Stock Performance

Shares of NASDAQ DNLI traded down $0.29 during midday trading on Thursday, reaching $18.60. 816,091 shares of the company traded hands, compared to its average volume of 942,911. The firm has a market cap of $2.68 billion, a PE ratio of -6.74 and a beta of 1.43. The stock’s 50-day simple moving average is $21.44 and its 200-day simple moving average is $24.63. Denali Therapeutics has a 12 month low of $14.56 and a 12 month high of $33.33.

Insider Transactions at Denali Therapeutics

In other Denali Therapeutics news, CEO Ryan J. Watts sold 29,266 shares of Denali Therapeutics stock in a transaction on Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $591,758.52. Following the sale, the chief executive officer now directly owns 260,721 shares in the company, valued at approximately $5,271,778.62. The trade was a 10.09 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Vicki L. Sato sold 3,080 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total transaction of $64,402.80. Following the transaction, the director now owns 107,976 shares in the company, valued at $2,257,778.16. This represents a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 47,940 shares of company stock valued at $973,442. Corporate insiders own 7.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Baird R W raised shares of Denali Therapeutics to a “strong-buy” rating in a report on Tuesday, January 7th. William Blair reissued an “outperform” rating on shares of Denali Therapeutics in a report on Wednesday, January 15th. HC Wainwright lowered their price objective on shares of Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. The Goldman Sachs Group decreased their target price on shares of Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 7th. Two equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $37.42.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.